Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN DON FOLKERTH

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1215985197
CMS profile
10174
Location
BEAVERCREEK, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$209.13

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $209.13 14

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN DON FOLKERTH

NPI 1215985197 · CMS profile ID 10174

Allopathic & Osteopathic Physicians / Internal Medicine

BEAVERCREEK, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $209.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.2304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672411411 CMS
Novartis Pharmaceuticals Corporation $16.1804/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660184469 CMS
PFIZER INC. $21.8404/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672414807 CMS
GlaxoSmithKline, LLC. $16.2304/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670758207 CMS
AstraZeneca Pharmaceuticals LP $11.2503/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685912095 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3203/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700384781 CMS
PFIZER INC. $11.1003/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672459700 CMS
AstraZeneca Pharmaceuticals LP $11.3303/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685825127 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.5302/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684726579 CMS
Amarin Pharma Inc. $15.5502/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699077641 CMS
Amgen Inc. $18.5202/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663075691 CMS
PFIZER INC. $14.6302/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672415411 CMS
AstraZeneca Pharmaceuticals LP $12.3502/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685601573 CMS
PFIZER INC. $11.0701/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672461767 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $209.13 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $8,820.08 1
PY2024 Principal investigator $75,861.80 1
PY2023 Principal investigator $369,654.75 14
PY2022 Recipient $202.26 1
PY2022 Principal investigator $2,132,299.27 89
PY2021 Principal investigator $5,447,139.77 65
PY2020 Principal investigator $527,432.45 9
PY2019 Principal investigator $510,064.93 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 12/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366123
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,798.74 12/15/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366093
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 11/30/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366121
Principal investigator 1 Sage Therapeutics, Inc. $200.00 11/23/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905460829
Principal investigator 1 Endo Pharmaceuticals Inc. $944.00 11/22/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185373
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $650.84 11/10/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366091
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $194.40 11/10/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366097
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $250.00 11/10/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366099
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,451.84 11/03/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366089
Principal investigator 1 Sage Therapeutics, Inc. $1,640.08 11/03/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905460264
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 10/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366119
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $200.00 10/20/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366087
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,708.96 10/20/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 10/14/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938699409
Principal investigator 1 Sage Therapeutics, Inc. $200.00 10/06/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905459047
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 09/30/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/23/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938696401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 09/23/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938696407
Principal investigator 1 Sage Therapeutics, Inc. $8,000.00 09/22/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMOR No dispute reported 06/30/2026 905458735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $520.00 09/16/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938693963
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,614.70 09/09/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366059
Principal investigator 1 Sage Therapeutics, Inc. $9,345.25 09/08/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905458393
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $51.00 09/02/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366067
Recipient Regeneron Pharmaceuticals, Inc. $202.26 09/01/2022 Covered Recipient Physician A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938602823
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 08/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366109
Principal investigator 1 Endo Pharmaceuticals Inc. $8,121.00 08/24/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,611.50 08/05/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938676702
Principal investigator 1 Sage Therapeutics, Inc. $7,535.97 08/04/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905457517
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 07/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.00 07/29/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938673929
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,199.92 07/27/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366061
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,147.10 07/27/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,760.00 07/22/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938667347
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $250.00 07/21/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366065
Principal investigator 1 Sage Therapeutics, Inc. $127.40 07/21/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905457091
Principal investigator 1 Sage Therapeutics, Inc. $18,657.16 07/14/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905456811
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,147.90 06/30/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366075
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 06/30/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 06/30/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938652279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/30/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938652287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,660.00 06/30/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938652293
Principal investigator 1 Sage Therapeutics, Inc. $260.00 06/28/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905456549
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $250.00 06/20/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366077
Principal investigator 1 Sage Therapeutics, Inc. $520.00 06/16/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905455963
Principal investigator 1 Innocoll Pharmaceuticals Limited $500.00 06/13/2022 Non-covered Recipient Entity
Midwest Clinical Research Center
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries No dispute reported 06/30/2026 957110141
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $109,922.47 06/13/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy No dispute reported 06/30/2026 904837913
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $325.42 06/09/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366071
Principal investigator 1 Sage Therapeutics, Inc. $3,578.38 06/09/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905455717
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,451.84 06/02/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366069
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 05/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366115
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,956.12 05/25/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366073
Principal investigator 1 Endo Pharmaceuticals Inc. $219.00 05/17/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185345
Principal investigator 1 Endo Pharmaceuticals Inc. $6,955.00 05/17/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185353
Principal investigator 1 Sage Therapeutics, Inc. $820.00 05/12/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905454671
Principal investigator 1 Sage Therapeutics, Inc. $33,742.54 05/12/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905454677
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 04/30/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366113
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $650.00 04/27/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366079
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/27/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS No dispute reported 06/30/2026 937167477
Principal investigator 1 Endo Pharmaceuticals Inc. $1,331.00 04/26/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $560.00 04/22/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938624937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 04/22/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938624939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,717.50 04/15/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938622961
Principal investigator 1 Sage Therapeutics, Inc. $254.80 04/14/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905453369
Principal investigator 1 Endo Pharmaceuticals Inc. $600.00 04/12/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,250.00 04/08/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938622237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 04/08/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938622239
Principal investigator 1 Innocoll Pharmaceuticals Limited $1,500.00 04/01/2022 Non-covered Recipient Entity
Midwest Clinical Research Center
Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty No dispute reported 06/30/2026 957110123
Principal investigator 1 Innocoll Pharmaceuticals Limited $1,000.00 04/01/2022 Non-covered Recipient Entity
Midwest Clinical Research Center
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries No dispute reported 06/30/2026 957110135
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 03/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366105
Principal investigator 1 Endo Pharmaceuticals Inc. $219.00 03/15/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185297
Principal investigator 1 Endo Pharmaceuticals Inc. $219.00 03/15/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185305
Principal investigator 1 Endo Pharmaceuticals Inc. $4,100.00 03/15/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185315
Principal investigator 1 Sage Therapeutics, Inc. $80.00 03/10/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905451643
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 02/28/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366103
Principal investigator 1 Endo Pharmaceuticals Inc. $4,100.00 02/15/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929185287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $191,384.10 02/11/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938615407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $191,384.10 02/11/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938615409
Principal investigator 1 Vertex Pharmaceuticals Incorporated $802,378.73 02/04/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Phase 2 Randomized Double - blind Placebo - controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty No dispute reported 06/30/2026 904836675
Principal investigator 1 Sage Therapeutics, Inc. $7,500.00 02/03/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
STUDY TO EVALUATE SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMORS No dispute reported 06/30/2026 905451045
Principal investigator 1 Innocoll Pharmaceuticals Limited $20,520.00 02/01/2022 Non-covered Recipient Entity
Midwest Clinical Research Center
Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty No dispute reported 06/30/2026 957110117
Principal investigator 1 Innocoll Pharmaceuticals Limited $34,720.00 02/01/2022 Non-covered Recipient Entity
Midwest Clinical Research Center
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries No dispute reported 06/30/2026 957110129
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 01/31/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $595.00 01/28/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2 RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF MODERNA MRNA-1273 VACCINE ADMINISTERED WITH CASIRIVIMAB+IMDEVIMAB IN HEALTHY ADULT VOLUNTEERS No dispute reported 06/30/2026 938614507
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/25/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366081
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 01/25/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366083
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,500.00 01/25/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2B 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL GROUP MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 950366085
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $386,253.46 01/15/2022 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy No dispute reported 06/30/2026 904834637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169,183.35 01/14/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 938613633
Principal investigator 1 Heron Therapeutics, Inc. $9,360.70 01/06/2022 Non-covered Recipient Entity
ERG Holding Company
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen No dispute reported 06/30/2026 920265483
Principal investigator 1 Siemens Medical Solutions USA, Inc. $10,260.00 01/06/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AMH Apparently Healthy) No dispute reported 06/30/2026 870517789